pretreatment factors adversely affecting survival included poor performance status, weight loss of > 10%, and more than two sites of metastases. Toxicity was not severe in either treatment arm, and only thrombocytopenia occurred significantly more often with FAB. It is contended that in the treatment of advanced gastric cancer, chemotherapy only exerts a relatively short-term and modest beneficial effect, most apparent in patients with intermediate tumor bulk. 5-FU remains the most active single agent, and combination chemotherapy has not yet proven its overall worth. Further studies are indicated comparing the most active combinations with 5-FU using optimal doses and schedules, and consideration must be given to the incorporation of no-treatment controls.
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tients, and determination of the level of activity of a drug has been generally based on cumulative analyses of a number of small studies. 7 ' 8 Combination chemotherapy studies in advanced-stage gastric cancer, initially most often incorporating 5-fluorouracil (5-FU), mitomycin C, or a nitrosourea and subsequently adding doxorubicin, have reported response rates in excess of 40% and on occasion > 50%.9-12 However, there have only been a limited number of randomized studies comparing these various combinations with individual drugs, and more recent studies have compared different drug combinations. 9, 10, [13] [14] [15] [16] An initial pilot study by Levi et al using the three-drug combination of 5-FU, doxorubicin paring this three-drug combination to the apparently most active single agent available, doxorubicin, based on the results of single-agent data published up to the time of initiation of the study. 5 " 3 A sufficiently large population with advanced-stage disease was entered to confidently define not only the treatment's comparative potential to produce disease regression, but also influence on survival. This report documents our experience in 203 patients with advanced-stage gastric cancer prospectively randomized to receive chemotherapy with either the single agent, doxorubicin, or the drug combination, FAB.
PATIENTS AND METHODS
All patients had primary adenocarcinoma of the stomach with histological proof of surgically unresectable, recurrent, or metastatic disease beyond the regional lymph nodes. To qualify for evaluation of objective tumor response to therapy, patients had to have at least one area of measurable or evaluable disease. This included bidimensionally measurable tumor masses, and in the case of malignant hepatomegaly, the liver margin had to be at least 5 cm below the costal margin on quiet respiration. Gastric lesions were considered measurable if dimensions were accurately determined on gastroscopy. Evaluable lesions were defined as lesions identified by radiography, nuclear scanning, or computerized tomographic (CT) scanning as evidence of primary or metastatic disease in which alterations of > 50% in diameter could be detected with serial assessment.
Other criteria for patient entry on study included an estimated survival of at least 2 months, no evidence of active infection or previous invasive cancer in other sites, or active heart disease that would preclude doxorubicin administration. No patient who had received prior chemotherapy was eligible, and any patient who received prior radiotherapy required a 4-week rest before entry. Adequate renal, bone marrow, and hepatic function were required as defined by a serum creatinine < 0.15 mg/L, a WBC count > 4,000/ALL, a platelet count > 100,000/C/L, and a serum bilirubin < 3.0 mg/dL.
Patients were stratified before randomization according to performance status by Eastern Cooperative Oncology Group (ECOG) criteria and the presence or absence of measurable or evaluable disease. Approval for the trial was obtained from the Medical Ethics or Research Review Committee of each participating institution, and patients were informed of the nature of their disease and gave informed consent. Treatment allocation was determined by a central randomization from the trial operations office.
The schedule for administration of doxorubicin as a single agent was 60 mg/m2 intravenously (IV) on day 1 and repeated at 21-day intervals. The three-drug combination schedule was 5-FU, 600 mg/m 2 IV days 1 and 8, doxorubicin, 40 mg/m 2 IV day 1, and BCNU, 100 mg/m2 IV day I. Courses of the first two drugs were repeated every 28 days, while BCNU was re-administered every 56 days. When necessary, drug dosages were modified according to the degree of myelosuppression observed with previous courses. The cumulative dose of doxorubicin was limited to 550 mg/m2 for both arms of the study.
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Complete remission was defined as complete resolution of all clinically detectable tumors. Partial remission was defined as a decrease in size of at least 50% of the principal measurable or evaluable parameter of disease, or a reduction of the sum of liver measurements below each costal margin at the midclavicular line and xyphoid process by at least 30% for a minimum of 4 weeks with no significant deterioration in weight (> 2.5%) or performance status (one score level). Stable disease was defined as < 50% regression of primary measurable or evaluable indicator lesions for at least 4 weeks, no new lesions appearing, and no significant deterioration in weight or performance status. Progressive disease was defined as an increase in size of any preexisting measurable or evaluable lesions by > 25%, appearance of new lesions, or significant deterioration in weight or performance status.
Statistical methods included a determination of 90% confidence limits for response rates observed; differences in response data according to baseline factors and toxicity rates were compared using the chi square statistic. Durations of response to treatment and survival statistics were assessed by the GehanWilcoxon and log-rank tests. For the assessment of treatment differences, covariate adjustment was made for the two stratification variables, stage (measurable and evaluable v nonmeasurable) and performance status (0 to 1 v 2 to 3 v 4).
RESULTS
Among the 203 patients entered on this study, 16 were unevaluable because of inadequate follow-up data (11 patients), treatment cancellation (three patients), and protocol violation (two patients). The characteristics of the 187 evaluable patients are presented in Table 1 . There were no significant imbalances between the two patient groups. The largest patient category (145 patients; 78%) had advanced measurable disease with measurable or evaluable indicator lesions. The majority (70%) had an ECOG performance status of 0 or 1, while 83 patients (44%) had undergone a previous gastric resection.
Among the 145 patients with measurable disease, objective remissions occurred in 13% of patients who received doxorubicin (90% confidence limits of 6% to 19%) and 40% of patients (90% confidence limits of 31% to 49%) who received FAB (P < .01), including complete remissions in two doxorubicin patients (3%) and in five FAB patients (7%). Table 2 presents the response rates for each treatment group according to initial characteristics, and apart from an overall significantly higher remission rate for FAB, patients with predominant metastatic disease in lymph nodes who received FAB achieved remission (76%) significantly more often (P < .05). Higher response rates for FAB patients were also observed when lung was the predomi- nant site of disease (100%), when pretreatment weight loss was > 10% (57%), and with previous gastric resection (46%), but the numbers in each subgroup were too small for these differences to be significant. Interestingly, older patients (> 60 years) receiving FAB responded as frequently as younger patients. Patients with good performance status (0 to 1) had a significantly higher response rate irrespective of their treatment allocation (P < .05).
The median time to achieve remission was similar for the two treatment groups (8 weeks for FAB and 6 weeks for doxorubicin). Time to disease progression for responding patients with measurable disease is indicated in Fig 1, and was significantly longer for the FAB patients as determined both by the Gehan-Wilcoxon test (P = .004) and the log-rank test (P = .05), with a median time of 28 weeks compared with 18 weeks for doxorubicin. The time to disease progression for the two treatment groups with nonmeasurable disease was not significantly different by either the Gehan-Wilcoxon test (P = . 41) or the log-rank test (P = .70). For the total patient population, a significant difference was observed with the Gehan-Wilcoxon test (P = .01), but was not reached with the log-rank test (P = .20), the median time to disease progression for FAB being 29 weeks, and 18 weeks for the doxorubicin patients.
The data for survival analysis in this study is quite mature because 92 of 94 patients receiving FAB and 88 of 93 patients receiving doxorubicin have died, and the duration of follow-up for surviving patients is in excess of 100 weeks and as long as 304 weeks. As indicated in Table 3 , at 60 weeks of follow-up, 12% of the doxorubicin patients and 16% of the FAB patients were alive, and at 100 weeks 6% of patients in both groups were alive. The maturity of this study is reflected by the fact that for the overall patient population, the Gehan-Wilcoxon test, which is sensitive to differences occurring early in time, demonstrated a significant survival advantage for patients receiving FAB (P = .01), but the log-rank test, which is sensitive to differences occurring later in time, did not reach statistical significance for the two treatment groups (P = . 14), as indicated in ent from the data in Table 3 , with the proportion of total patients surviving up to 40 weeks clearly favoring those who received FAB, but thereafter there was progressively less difference up to 100 weeks of survival.
Among the patients with measurable disease, a significant difference in survival was observed by both the Gehan-Wilcoxon test (P = .003) and the log-rank test (P = .01), as indicated in Fig 3. However, there was little difference in survival for the nonmeasurable patients by either the Gehan-Wilcoxon test (P = .95) or the log-rank test (P = .67), with a median survival for FAB of 43 weeks and for doxorubicin of 36 weeks.
Prognostic factors adversely effecting survival to a significant degree irrespective of treatment allocation included weight loss of > 10%, performance status of 2 to 4, and more than two sites of metastases (usually including either liver or peritoneum, or both). Age, sex, histological grade, and site of primary tumor showed no significant effect, and although patients with prior gastric resection had a somewhat longer survival, this was not significant by the log-rank test (P = .07).
A summary of treatment-related toxicities is presented in Table 4 . Myelosuppression was the dose-limiting toxicity, particularly leukopenia, although only 8% of patients receiving FAB and 5% receiving doxorubicin had WBC count nadirs below 2,000/1L at any time throughout treatment. Life-threatening infections occurred in four patients receiving doxorubicin, with three han-Wilcoxon test, P = .01; log-rank 0 20 analysis, P =.14. deaths, and in six patients receiving FAB, with one death. Thrombocytopenia was the only toxicity occurring significantly more often in FAB patients (P < .01) and tended to occur with later courses of treatment. No life-threatening hemorrhage occurred with either treatment group. There was little difference in the incidence and severity of other toxicities with either therapy and no patient withdrew from treatment because of these. Moderate to total reversible alopecia occurred in 75% of patients and was equivalent in both treatment groups. Doxorubicin-related cardiomyopathy occurred in one patient who received FAB and ultimately resulted in death. 
OS'RAPY
Overall, toxicity was generally acceptable and satisfactorily managed with appropriate drugdose modification.
DISCUSSION
It is difficult at this time to confidently define the precise value of chemotherapy in the management of advanced-stage gastric cancer and what drugs represent an optimum approach. There are a number of reasons for this, including the failure to incorporate either no treatment controls or consistent single-agent arms in randomized trials evaluating combination chemotherapy.5,9,10,13 The mix of patient populations ADRIA r AB included and the variation in drug choices, doses, and schedules between the various studies, which indicate an apparent advantage for three-drug combinations incorporating 5-FU, doxorubicin, and mitomycin C or a nitrosourea, have all added to these difficulties in interpretation."' 16 The results from this study highlight some of these problems and provide directions for future studies that may resolve these difficulties.
The single-agent arm of this trial using doxorubicin includes the largest number of consecutive advanced-stage gastric cancer patients treated with this agent. The response rate of 13%, with 90% confidence limits of 6% to 19%, among the 70 previously untreated patients evaluated with measurable disease indicates that the degree of activity of doxorubicin is probably less than the 22% to 24% response rate reported from the two earlier studies with the largest number of patients treated (37 and 17 patients, respectively). 5,13
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In view of the fact that the largest studies evaluating 5-FU as a single agent have included 54 to 72 patients in each study and obtained response rates of 20% to 27%, this drug must still be considered the most active single agent and the standard for comparison of any drug combinations.1' 2 , 7 In this context, it is pertinent to note that no studies reported have demonstrated a significant survival advantage for combination chemotherapy when compared with 5-FU, and when such advantages for drug combinations were reported the single-agent comparison has been either a nitrosourea or doxorubicin.
9 ,1 0 ,13, [18] [19] [20] What then are the clinical implications of advantages observed for FAB in this study? Certainly, the FAB combination was associated with a significantly higher response rate (40%, with 90% confidence limits of 31% to 49%) than doxorubicin among the patients with measurable disease, and there was also a significant survival advantage for FAB in this group of patients. However, for the total patient population, incorporating the group with nonmeasurable disease, this survival advantage was principally apparent between 20 to 40 weeks of follow-up, as indicated by the significant Gehan-Wilcoxon test, but declined with continued follow-up, as indicated by the lack of significance for the treatment arms with log-rank analysis. Furthermore, the most favorable influences of therapy were seen in patients with predominant lymph node involvement, two or less sites of metastases, weight loss of < 10%, and performance status of 0 to 1. All of this suggests that it is the patients with an intermediate bulk of tumor who derive the greatest benefit from FAB. This implies that FAB exerts only a modest and relatively short-term effect on the cancer, apparent in survival benefit for the patients with intermediate tumor bulk, but for those with larger or relatively small tumor volumes, the natural history of the disease is either too advanced or still sufficiently long to effectively minimize relatively small influences of therapy.
Furthermore, it is recognized that confident determination of alterations in tumor size can be very difficult, particularly when dealing with predominant intraabdominal disease assessed by CT scan or endoscopy. This, together with a range of degrees of tumor bulk present in the study populations and modest levels of efficacy of available chemotherapy in gastric cancer, supports the point that the most appropriate measure of the influence of chemotherapy in future studies is determination of survival with sufficient duration of follow-up to confidently assess this.
It is clear that in this study the FAB combination exerted a more favorable biological effect than doxorubicin and is comparable with that observed with the most active drug combinations reported elsewhere. 12,14-16 Whether this is due to a relative lack of activity of doxorubicin as a single agent, an additive or even synergistic effect of the three drugs in the combination, or principally to the 5-FU component, cannot be answered from this study. Attempts by some investigators of other recent combination chemotherapy studies to unravel the influences of individual drugs within the combinations studied, fail to clarify this issue.14-1621 A recent study comparing 5-FU, 5-FU and doxorubicin, and 5-FU, doxorubicin, and mitomycin C showed no survival advantage for the combinations, and again raises the specter of the degree of activity of 5-FU in optimum dose and schedule as a single agent.
2 0 Nevertheless, this study has been criticized on the basis of small numbers and uncertain mix of patients with gastric cancer. 16 Clearly, a proper randomized comparative study is required involving adequate numbers of patients and careful stratification of important prognostic factors.
Excessive toxicity was not observed on either treatment arm of this study, and only thrombocytopenia occurred significantly more often with FAB and the BCNU was most likely responsible. Only 8% of patients receiving FAB had leukocyte count nadirs below 2,000/LL, and as recent data suggests, a dose response relationship in which patients with nadir leukocyte counts below 2,000//iL had the most favorable outcome, it is conceivable that the maximum potential for this combination was not achieved.15, 21 , 22 This area should be further explored with properly constructed randomized studies, including both single agents and combinations.
Interest has been generated by two recent reports that the incorporation of an antifolate into the combination of 5-FU and doxorubicin may improve response rates and survival in advancedstage gastric cancer, but these are uncontrolled studies and of a preliminary nature.
